181 S Franklin Ave, 4th Floor Valley Stream, NY 11581 24 Hours a Day, 7 Days a Week
The Stile Newsletter - Issue #929
Past Editions
Subject:  02.13.2026 The Stile Newsletter Issue #929

The Stile Newsletter Issue # 929 .

ISSUE #929 - 02/13/2026


Please visit us at

www.stileintl.com 

for all your import needs:

  • Tracking your shipments
  • printing documents
  • viewing your entries
  • past & present editions of the Stile Newsletter

If you need any assistance with Username and/or Password,

please contact:

williamortiz@stileintl.com

Executive Vice President



jmenendez@stileintl.com

Director of IT and Management


Ambassador Greer Signs the United States–Argentina Agreement on Reciprocal Trade and Investment - USTR

February 05, 2026

WASHINGTON – Today, Ambassador Jamieson Greer joined Argentina’s Minister of Foreign Affairs, International Trade, and Worship Pablo Quirno in signing the United States–Argentina Agreement on Reciprocal Trade and Investment (ARTI).

“The deepening partnership between President Trump and President Milei serves as a model of how countries in the Americas, from Alaska to Tierra del Fuego, can advance our shared ambitions and safeguard our economic and national security,” said Ambassador Greer. “The U.S.-Argentina Agreement lowers long-standing trade barriers and provides significant market access for American exporters, ranging from motor vehicles to a wide array of agricultural products. I thank Argentina’s Minister Pablo Quirno for his commitment to achieving a stronger, more balanced partnership.”

To read the text of the Agreement between the United States of America and Argentina on Reciprocal Trade and Investment, click here. To read the tariff schedule, click here.

To read the Joint Statement on Framework for United States–Argentina Agreement on Reciprocal Trade and Investment, click here. 

To read the Fact Sheet, click here.




Federal Register Notices: 


CBP Expects Record-Setting Year for Cut Flower Inspections - CBP

WASHINGTON — U.S. Customs and Border Protection agriculture specialists are on track for another record-setting year as they work to keep America safe by imported cut flower stems ahead of Valentine’s Day.

As the busiest season for flower imports approaches, CBP has already inspected more than 1 billion cut flowers, intercepting over 600 harmful pests and plant diseases from hitch-hiking into the United States. By the time Valentine’s Day arrives, CBP expects to top last year’s record of 1.3 billion stem inspections.

“Every cut flower inspected by CBP is a testament to our vigilance and unwavering commitment to preventing the entry of plant pests and diseases without compromising our agricultural protection,” said Acting Executive Director Suzette Kelly, of CBP’s Agriculture Programs and Trade Liaison.

Although a relatively small number of harmful pests are found among the millions of stems inspected, even a single one can cause significant damage to U.S. crops. The most common pest to date, Entyloma Meridaonale, is a pathogenic fungus that can lead to the death of leaf tissue, reducing the plant's ability to photosynthesize. The second-most common pest, Noctuidae (moth larvae), causes severe damage by cutting seedlings at the base, defoliating plants, or boring into fruits and stems.

Miami International Airport remains the primary port of entry for commercial flower stems, processing approximately 88% of cut flower imports, which come from countries like Colombia, Ecuador and Mexico. The ports at Otay Mesa and Los Angeles International Airport handle most of the remaining 12%. Roses, chrysanthemums and carnations are the three most common types of imported flowers.

People who wish to import flowers, plant materials, and other agricultural items should consult the CBP Information Center section on the CBP website or call (877) 227-5511. Check here for more information on each country of origin’s marking requirements for fresh cut flowers . Follow CBP on X @CBP for breaking news, current events, human interest stories and photos.


FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs - Food & Drug Administration

Today (2/06/26), the U.S. Food and Drug Administration is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies — including Hims & Hers and other compounding pharmacies — as similar alternatives to FDA-approved drugs. These actions are aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy. We take seriously any potential violations of the Federal Food, Drug, and Cosmetic Act.

The FDA is also taking steps to combat misleading direct-to-consumer advertising and marketing following warning letters that were sent in the fall of 2025. In promotional materials, companies cannot claim that non-FDA-approved compounded products are generic versions or the same as drugs approved by FDA. They also cannot state compounded drugs use the same active ingredient as the FDA-approved drugs or that compounded drugs are clinically proven to produce results for the patient.

The FDA will use all available compliance and enforcement tools within its authorities to address unsubstantiated claims and associated public health concerns. Entities engaged in the manufacture, distribution, or marketing of unapproved compounded GLP-1 products should be aware that failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.

Related Information


  

FDA Launches PreCheck Pilot Program to Strengthen Domestic Pharmaceutical Manufacturing - FDA

Agency Now Accepting Requests to Participate in Initiative to Enhance Regulatory Predictability and Streamline New Manufacturing Facility Assessment

The U.S. Food and Drug Administration today began accepting requests to participate in the FDA PreCheck pilot program. FDA PreCheck is designed to strengthen the domestic pharmaceutical supply chain by increasing regulatory predictability, facilitating the construction of manufacturing sites in the U.S., and streamlining aspects of pharmaceutical manufacturing facility assessments in advance of a specific product application.

"After 35 years of globalists taking pharmaceutical manufacturing overseas, the FDA is taking bold steps to bring it back," said FDA Commissioner Marty Makary, M.D., M.P.H. "The PreCheck program is one of several powerful incentives we are providing to make the U.S. pharmaceutical manufacturing sector more resilient and competitive."

The agency will select an initial cohort of new pharmaceutical manufacturing facilities and begin conducting PreCheck activities in 2026. Facilities will be selected based on overall alignment with national priorities across multiple selection criteria, such as products to be manufactured, phase of facility development, timeline to producing pharmaceutical products for the U.S. market, and innovation in facility development. Additional priority consideration will be given to facilities producing critical medications for the U.S. market.

The FDA incorporated extensive industry feedback into the program design based on comments made during the "Onshoring Manufacturing of Drugs and Biological Products" public meeting held on Sept. 30, 2025, and public comments received through Federal Register publication. Industry strongly supported early engagement during facility development and streamlined documentation processes. 

FDA PreCheck consists of two phases. In Phase 1, the Facility Readiness Phase, selected manufacturers will engage with FDA for early technical advice before a facility is operational through pre-operational reviews and utilization of a facility-specific Drug Master File to facilitate efficient evaluation of facility-specific elements prior to, and in support of, the submission of a drug application. In Phase 2, the Application Submission Phase, FDA and applicants build upon Phase 1 and engage through pre-submission meetings and inspections to resolve issues and expedite assessments of manufacturing information in a drug application.

For more information, including eligibility and selection criteria, visit the FDA PreCheck web page.

  

FTC Issues Second Report to Congress on its Work to Fight Ransomware and other Cyberattacks - Federal Trade Commission

The Federal Trade Commission issued a second report to Congress detailing the agency’s efforts to fight against ransomware and other cyberattacks.

The report is mandated by the Reporting Attacks from Nations Selected for Oversight and Monitoring Web Attacks and Ransomware from Enemies Act (RANSOMWARE Act), which requires the Commission to submit reports to Congress on its work to combat cyberattacks. In its initial report from 2023, the agency provided an overview of the FTC’s activities concerning China, Russia, North Korea, and Iran and the FTC’s efforts to combat ransomware—a type of cyber-related attack in which bad actors hold data or computer access hostage until they receive payment—and other types of cyberattacks.

The 2025 Ransomware Report provides an update on those activities and highlights the FTC’s continued contribution to the fight against ransomware and other cyberattacks. The report discusses the FTC’s data security enforcement program aimed at ensuring companies take reasonable steps to protect the personal data they hold noting that the FTC has brought more than 90 enforcement actions with favorable outcomes to date, including settlements with GoDaddy and Illuminate Education.

The agency has also pursued bad actors involved in tech support scams and worked to educate the public and businesses on how to secure and protect data from cyberattacks. Specifically, the FTC’s consumer and business education efforts include up-to-date alerts and advice about malware, cybersecurity, and tech support scams.

The Commission votes to approve the 2025 report was 2-0.

The Federal Trade Commission works with counterpart agencies to promote sound antitrust, consumer protection, and data privacy enforcement and policy. The FTC will never demand money, make threats, tell you to transfer money, or promise you a prize. For the latest news and resources, follow the FTC on social media, subscribe to press releases and subscribe to the FTC International Monthly.








 
 

Stay Informed – Get the Latest Updates Straight to Your Inbox!

Sign up for our newsletter and never miss important news like our latest Special Notices, Tariff Updates, and Industry Alerts.

Simply fill out the form and get instant access to timely updates and valuable information.

Got Questions? Let’s Talk

Our experienced teams prioritize your needs, delivering solutions swiftly and professionally. We believe in blending today’s needs with tomorrow’s technology at competitive prices, ensuring your satisfaction with every shipment. At Stile Associates, we don’t just move your cargo; we move your business forward. Contact us for questions and concerns about our services. .


FacebookTwitterInstagram
Learn more about our freight forwarding company